Teva Pharmaceutical Industries found positive results in the Phase III SPACE trial of Ajovy for episodic migraine in young patients aged 6-17. The trial showed significant reduction in migraine frequency with a good safety profile, indicating potential benefits for children and adolescents suffering from migraines.